The Technology

Kinases, the targets of kinase inhibitor drugs, are enzymes that regulate lipid or protein phosphorylation in cells, which in-turn determine phenotype. Dysregulation leads to pathologies such as cancer, inflammatory and autoimmune diseases.

Specific protein phosphorylation, and hence kinase activity, can only be measured unequivocally using liquid chromatography - tandem mass spectrometry (LC-MS/MS) based phosphoproteomics.

Kinomica has developed KinoScan^TM, a technology platform integrating state-of-the-art label free LC-MS/MS phosphoproteomics and innovative bioinformatic algorithms to investigate and monitor kinases and thus, global cellular signalling pathway activities.

KinoScan^TM can interpret patterns in >10,000 phosphorylation signatures in a single analysis to directly inform on therapeutic R&D and impact clinical decision-making.

A key feature is that it provides a snap-shot & direct read-out of kinases and other drug target activities

Kinase activities are ranked within each sample and compared across samples to identify markers of response or resistance. Such markers stratify responders from non-responders to therapies more accurately than current companion diagnostics (CDx). We partner with clients to help identify predictive biomarkers for therapies including; small molecule inhibitors, monoclonal antibodies and cell based immuno-therapies.